Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended June 30,
	2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	316	$	235	$	551	$	190	$	158	$	348
Urology and Pelvic Health	285		112		397		162		66		228
Cardiac Rhythm Management	314		210		524		208		143		351
Electrophysiology	34		62		95		22		30		51
Neuromodulation	194		53		247		100		23		122
Interventional Cardiology	398		392		790		189		306		495
Peripheral Interventions	260		213		473		189		151		340
Specialty Pharmaceuticals	—		—		—		60		8		68
Net Sales	$	1,800	$	1,277	$	3,077	$	1,118	$	885	$	2,003

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales for the first six months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.

	Six Months Ended June 30,
	2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	596	$	454	$	1,050	$	445	$	345	$	790
Urology and Pelvic Health	542		216		758		400		161		560
Cardiac Rhythm Management	590		403		993		463		325		788
Electrophysiology	64		115		179		53		72		126
Neuromodulation	345		99		444		250		63		313
Interventional Cardiology	741		745		1,486		486		642		1,128
Peripheral Interventions	498		407		906		413		319		732
Specialty Pharmaceuticals	10		4		13		97		12		109
Net Sales	$	3,386	$	2,443	$	5,829	$	2,607	$	1,939	$	4,546

	Three Months Ended June 30,				Six Months Ended June 30,
Geographic Regions	2021		2020		2021		2020
U.S.	$	1,800	$	1,058	$	3,376	$	2,510
EMEA (Europe, Middle East and Africa)	662		416		1,266		968
APAC (Asia-Pacific)	520		410		994		819
LACA (Latin America and Canada)	95		51		180		140
Medical Devices	3,077		1,935		5,816		4,437
U.S.	—		60		10		97
International	—		8		4		12
Specialty Pharmaceuticals	—		68		13		109
Net Sales	$	3,077	$	2,003	$	5,829	$	4,546
Emerging Markets(1)	$	359	$	268	$	676	$	542

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.